金吾财讯 | Revvity（RVTY）宣布收购总部位于法国的生物技术公司Human Cell Design，该公司专注开发糖尿病、肥胖等代谢疾病相关人体细胞模型。本次交易财务细节未对外披露，交易预计2026年第四季度完成，尚需通过监管审批及满足常规交割条件。收购完成后，Human Cell Design的人胰腺β细胞模型将纳入Revvity生命科学产品线，提升其在GLP-1及其他代谢疾病疗法的药物发现与筛选实力。同时，被收购技术还将拓展Revvity在再生医学、细胞疗法领域的应用空间。
金吾财讯 | Revvity（RVTY）宣布收购总部位于法国的生物技术公司Human Cell Design，该公司专注开发糖尿病、肥胖等代谢疾病相关人体细胞模型。本次交易财务细节未对外披露，交易预计2026年第四季度完成，尚需通过监管审批及满足常规交割条件。收购完成后，Human Cell Design的人胰腺β细胞模型将纳入Revvity生命科学产品线，提升其在GLP-1及其他代谢疾病疗法的药物发现与筛选实力。同时，被收购技术还将拓展Revvity在再生医学、细胞疗法领域的应用空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.